Biohaven Ltd. Interest Income, Debt Securities, Operating
Biohaven Ltd. (BHVN) reported Interest Income, Debt Securities, Operating of $1.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeDebtSecuritiesOperating · last filed 2026-08-10
- Biohaven Ltd. interest income, debt securities, operating for the quarter ending 2026-06-30 was $1.24M, a 59.72% decline year-over-year.
- Biohaven Ltd. interest income, debt securities, operating for the quarter ending 2026-03-31 was $1.56M, a 51.61% decline year-over-year.
- Biohaven Ltd. interest income, debt securities, operating for the quarter ending 2025-12-31 was $1.18M, a 78.78% decline year-over-year.
- Biohaven Ltd. interest income, debt securities, operating for the quarter ending 2025-09-30 was $2.15M, a 43.98% decline year-over-year.
- Biohaven Ltd. interest income, debt securities, operating for fiscal 2025 was $9.64M, a 33.43% decline from fiscal 2024.
- Biohaven Ltd. interest income, debt securities, operating for fiscal 2024 was $14.48M, a 38.01% increase from fiscal 2023.
- Biohaven Ltd. interest income, debt securities, operating for fiscal 2023 was $10.49M, a 621.46% increase from fiscal 2022.
- Biohaven Ltd. interest income, debt securities, operating for fiscal 2022 was $1.45M.
| Period end | Interest Income, Debt Securities, Operating 3 month | Interest Income, Debt Securities, Operating 6 month | Interest Income, Debt Securities, Operating 9 month | Interest Income, Debt Securities, Operating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.24M 10-Q · filed 2026-08-10 | $2.80M 10-Q · filed 2026-08-10 | $3.98M derived: sum of 3 quarters · filed 2026-08-10 | $6.13M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $1.56M 10-Q · filed 2026-05-04 | $2.74M derived: sum of 2 quarters · filed 2026-05-04 | $4.90M derived: sum of 3 quarters · filed 2026-05-04 | $7.97M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.33M derived: sum of 2 quarters · filed 2026-03-02 | $6.41M derived: sum of 3 quarters · filed 2026-08-10 | $9.64M 10-K · filed 2026-03-02 |
| 2025-09-30 | $2.15M 10-Q · filed 2025-11-10 | $5.23M derived: sum of 2 quarters · filed 2026-08-10 | $8.46M 10-Q · filed 2025-11-10 | $14.02M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $3.08M 10-Q · filed 2026-08-10 | $6.30M 10-Q · filed 2026-08-10 | $11.87M derived: sum of 3 quarters · filed 2026-08-10 | $15.71M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $3.23M 10-Q · filed 2026-05-04 | $8.79M derived: sum of 2 quarters · filed 2026-05-04 | $12.64M derived: sum of 3 quarters · filed 2026-05-04 | $15.64M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.41M derived: sum of 2 quarters · filed 2026-03-02 | $12.41M derived: sum of 3 quarters · filed 2026-03-02 | $14.48M 10-K · filed 2026-03-02 |
| 2024-09-30 | $3.84M 10-Q · filed 2025-11-10 | $6.84M derived: sum of 2 quarters · filed 2025-11-10 | $8.91M 10-Q · filed 2025-11-10 | $11.49M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $3.00M 10-Q · filed 2025-08-11 | $5.07M 10-Q · filed 2025-08-11 | $7.64M derived: sum of 3 quarters · filed 2026-03-02 | $9.93M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $2.07M 10-Q · filed 2025-05-12 | $4.64M derived: sum of 2 quarters · filed 2026-03-02 | $6.92M derived: sum of 3 quarters · filed 2026-03-02 | $9.15M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.86M derived: sum of 2 quarters · filed 2026-03-02 | $7.08M derived: sum of 3 quarters · filed 2026-03-02 | $10.49M 10-K · filed 2026-03-02 |
| 2023-09-30 | $2.28M 10-Q · filed 2024-11-12 | $4.50M derived: sum of 2 quarters · filed 2024-11-12 | $7.91M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $2.23M 10-Q · filed 2024-08-09 | $5.63M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $3.38M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $1.45M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |